Maurer M, Giménez-Arnau AM, Sussman G, et al. - Via a phase 2b dose-finding trial, experts randomized individuals (n = 382) to receive ligelizumab at a dose of 24 mg, 72 mg, or 240 mg, omalizumab at a dose of 300 mg, or placebo, given subcutaneously every 4 weeks for a period of 20 weeks, or a single 120-mg dose of ligelizumab in order to ascertain the dose-response association of ligelizumab and the efficiency and safety of ligelizumab in comparison with omalizumab and placebo in individuals who have moderate-to-severe chronic spontaneous urticaria that was incompletely controlled with H₁-antihistamines at approved or increased doses, alone or in combination with H₂-antihistamines or leukotriene-receptor antagonists. No safety interests concerning ligelizumab or omalizumab were noted. Comprehensive control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg was achieved by a higher proportion of individuals, in comparison with omalizumab or placebo.